DK3278803T3 - Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor - Google Patents
Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor Download PDFInfo
- Publication number
- DK3278803T3 DK3278803T3 DK16771410.4T DK16771410T DK3278803T3 DK 3278803 T3 DK3278803 T3 DK 3278803T3 DK 16771410 T DK16771410 T DK 16771410T DK 3278803 T3 DK3278803 T3 DK 3278803T3
- Authority
- DK
- Denmark
- Prior art keywords
- dosage form
- pharmaceutical dosage
- solid pharmaceutical
- parp inhibitor
- parp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510157453 | 2015-04-03 | ||
| PCT/CN2016/078262 WO2016155655A1 (zh) | 2015-04-03 | 2016-04-01 | Parp抑制剂固体药物剂型及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3278803T3 true DK3278803T3 (da) | 2022-08-29 |
Family
ID=57003934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16771410.4T DK3278803T3 (da) | 2015-04-03 | 2016-04-01 | Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11179392B2 (da) |
| EP (1) | EP3278803B1 (da) |
| JP (1) | JP6878398B2 (da) |
| KR (1) | KR102013440B1 (da) |
| CN (1) | CN107405349B (da) |
| AU (1) | AU2016239141B2 (da) |
| CA (1) | CA2981627C (da) |
| DK (1) | DK3278803T3 (da) |
| ES (1) | ES2922637T3 (da) |
| WO (1) | WO2016155655A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61556B1 (sr) * | 2016-04-01 | 2021-04-29 | Impact Therapeutics Inc | Postupak dobijanja 1-(arilmetil) hinazolin-2,4 (1h, 3h)-diona |
| CA3094591C (en) | 2018-04-06 | 2024-03-26 | Capsugel Belgium Nv | Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)] |
| WO2019207498A1 (en) * | 2018-04-25 | 2019-10-31 | Biophore India Pharmaceuticals Pvt. Ltd | Solid forms of 8-fluoro-2-{4-[(methylamino)methyl] phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd] indol-6-one ((1s,4r)-7,7dimethyl-2-oxobicyclo [2.2.1] hept-1-yl) methanesulfonic acid salt (rucaparib camsylate) and the prerparation thereof |
| CN116322680A (zh) * | 2020-07-24 | 2023-06-23 | 上海瑛派药业有限公司 | Parp抑制剂的联合用药方案 |
| CN114053415A (zh) * | 2020-07-30 | 2022-02-18 | 江苏天士力帝益药业有限公司 | Tsl-1502复方药物组合 |
| WO2022099442A1 (zh) * | 2020-11-10 | 2022-05-19 | 上海瑛派药业有限公司 | 5-氟-1-(4-氟-3-(4-(嘧啶-2-基)哌嗪-1-羰基)苄基)喹唑啉-2,4(1h,3h)-二酮的结晶形式及其制备 |
| KR20230163467A (ko) * | 2021-03-26 | 2023-11-30 | 임팩트 테라퓨틱스 (상하이), 인코포레이티드 | Parp 억제제의 경구 캡슐 및 이의 제조 방법 |
| WO2023138667A1 (zh) * | 2022-01-21 | 2023-07-27 | 上海瑛派药业有限公司 | Senaparib和替莫唑胺的复方制剂及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1885338A1 (en) * | 2005-05-19 | 2008-02-13 | Pfizer, Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| JP2007131577A (ja) * | 2005-11-10 | 2007-05-31 | Mochida Pharmaceut Co Ltd | ３−クロメニル−ピリドキナゾリン−１−オン誘導体 |
| KR20090118982A (ko) | 2007-02-23 | 2009-11-18 | 아베라 파마슈티칼스, 인크. | 약학 제제 |
| ME02640B (me) * | 2008-10-07 | 2017-06-20 | Kudos Pharm Ltd | Farmaceutske formulacije 514 |
| WO2010078897A1 (en) * | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof |
| CN103443085B (zh) * | 2011-03-14 | 2016-03-23 | 南京英派药业有限公司 | 喹唑啉二酮及其应用 |
| TWI527800B (zh) * | 2011-04-01 | 2016-04-01 | 南京英派藥業有限公司 | 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用 |
| CN102731416A (zh) * | 2011-04-01 | 2012-10-17 | 南京英派药业有限公司 | 1-(芳基甲基)-喹唑啉-2，4-二酮作为parp抑制剂及其应用 |
| US20150011525A1 (en) * | 2011-09-13 | 2015-01-08 | Isp Investments Inc. | Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer |
| CN104066723B (zh) * | 2011-11-01 | 2016-06-29 | 南京英派药业有限公司 | 1-(芳基甲基)-5,6,7,8-四氢喹唑啉-2,4-二酮和相关化合物及其应用 |
-
2016
- 2016-04-01 WO PCT/CN2016/078262 patent/WO2016155655A1/zh active Application Filing
- 2016-04-01 CN CN201680017862.2A patent/CN107405349B/zh active Active
- 2016-04-01 JP JP2018502308A patent/JP6878398B2/ja active Active
- 2016-04-01 US US15/562,730 patent/US11179392B2/en active Active
- 2016-04-01 ES ES16771410T patent/ES2922637T3/es active Active
- 2016-04-01 DK DK16771410.4T patent/DK3278803T3/da active
- 2016-04-01 AU AU2016239141A patent/AU2016239141B2/en active Active
- 2016-04-01 CA CA2981627A patent/CA2981627C/en active Active
- 2016-04-01 EP EP16771410.4A patent/EP3278803B1/en active Active
- 2016-04-01 KR KR1020177031919A patent/KR102013440B1/ko active IP Right Grant
-
2021
- 2021-10-18 US US17/503,957 patent/US20220031702A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220031702A1 (en) | 2022-02-03 |
| EP3278803A4 (en) | 2018-11-07 |
| CA2981627A1 (en) | 2016-10-06 |
| KR102013440B1 (ko) | 2019-08-22 |
| JP6878398B2 (ja) | 2021-05-26 |
| KR20170132881A (ko) | 2017-12-04 |
| CN107405349B (zh) | 2021-03-02 |
| CN107405349A (zh) | 2017-11-28 |
| JP2018510221A (ja) | 2018-04-12 |
| US11179392B2 (en) | 2021-11-23 |
| AU2016239141A1 (en) | 2017-11-09 |
| EP3278803A1 (en) | 2018-02-07 |
| ES2922637T3 (es) | 2022-09-19 |
| CA2981627C (en) | 2024-02-20 |
| AU2016239141B2 (en) | 2019-04-18 |
| WO2016155655A1 (zh) | 2016-10-06 |
| US20180071290A1 (en) | 2018-03-15 |
| EP3278803B1 (en) | 2022-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301217I2 (nl) | tirzepatide en farmaceutisch aanvaardbare zouten daarvan | |
| DK3317286T3 (da) | Cykliserede sulfamoylarylamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b | |
| DK3302565T3 (da) | Faste doseringsformer af palbociclib | |
| DK3661921T3 (da) | Selektive hæmmere af nlrp3-inflammasom | |
| DK3487505T3 (da) | Indgivelse og dosering af diaminophenothiaziner | |
| DK3244948T3 (da) | Bestemmelse af medikamentdosis | |
| DK3259253T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3212230T3 (da) | Dosering og indgivelse af ikke-fucosylerede anti-CD40-antistoffer | |
| DK3278803T3 (da) | Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor | |
| KR102068915B9 (ko) | 조직 인자 경로 억제제 항체 및 그의 용도 | |
| DK3359241T3 (da) | Formuleringer af pthrp-analoger, transdermale plastre deraf og anvendelser deraf | |
| DK3514153T3 (da) | Pyrimidinforbindelse og farmaceutisk anvendelse deraf | |
| MA46193A (fr) | Inhibiteurs hétéroaryles de pad4 | |
| DK3313833T3 (da) | Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase | |
| DK3594343T3 (da) | Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft | |
| DK3319609T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer | |
| DK3380525T3 (da) | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf | |
| DK3275453T3 (da) | Farmaceutisk sammensætning med silibinin og ve | |
| DK3355890T3 (da) | Humane plasmakallikreininhibitorer | |
| DK3240821T3 (da) | Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde | |
| DK2958573T3 (da) | Farmaceutiske formuleringer af nitrit og anvendelser deraf | |
| DK3383397T3 (da) | Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin | |
| DK3386956T3 (da) | Fumagillolderivater og polymorfer deraf | |
| DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf |